Published in N Engl J Med on April 04, 1991
Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol Rev (2008) 10.28
Human hepatic stellate cell lines, LX-1 and LX-2: new tools for analysis of hepatic fibrosis. Gut (2005) 5.39
Transforming growth factor-beta in disease: the dark side of tissue repair. J Clin Invest (1992) 4.49
Hepatic expression of mature transforming growth factor beta 1 in transgenic mice results in multiple tissue lesions. Proc Natl Acad Sci U S A (1995) 3.25
Cytokine therapeutics: lessons from interferon alpha. Proc Natl Acad Sci U S A (1994) 2.90
Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma. Nat Rev Cancer (2013) 2.87
In vivo inhibition of rat stellate cell activation by soluble transforming growth factor beta type II receptor: a potential new therapy for hepatic fibrosis. Proc Natl Acad Sci U S A (1999) 2.17
Expression of transforming growth factor-beta 1 in dystrophic patient muscles correlates with fibrosis. Pathogenetic role of a fibrogenic cytokine. J Clin Invest (1995) 2.06
Role of Kupffer cells in the pathogenesis of liver disease. World J Gastroenterol (2006) 1.84
Hepatic fibrosis, glomerulosclerosis, and a lipodystrophy-like syndrome in PEPCK-TGF-beta1 transgenic mice. J Clin Invest (1997) 1.79
Smad2 and Smad3 play different roles in rat hepatic stellate cell function and alpha-smooth muscle actin organization. Mol Biol Cell (2005) 1.65
Differential expression of matrix-metalloproteinase-1 and -2 genes in normal and fibrotic human liver. Am J Pathol (1994) 1.64
Association of Interferon- and transforming growth factor β-regulated genes and macrophage activation with systemic sclerosis-related progressive lung fibrosis. Arthritis Rheumatol (2014) 1.58
Transforming growth factors beta 1 and beta 2 are differentially expressed in fibrotic liver disease. Am J Pathol (1991) 1.55
Hepatocyte growth factor (HGF) inhibits collagen I and IV synthesis in hepatic stellate cells by miRNA-29 induction. PLoS One (2011) 1.42
Regulation of the muscle fiber microenvironment by activated satellite cells during hypertrophy. FASEB J (2013) 1.42
Regulation of transforming growth factor-beta 1 expression by the hepatitis B virus (HBV) X transactivator. Role in HBV pathogenesis. J Clin Invest (1996) 1.33
Role of cytokines and chemokines in non-alcoholic fatty liver disease. World J Gastroenterol (2012) 1.32
Involvement of transforming growth factor-beta in the formation of fibrotic lesions in carcinoid heart disease. Am J Pathol (1993) 1.30
Transforming growth factor-beta (TGF-beta) isoforms in rat liver regeneration: messenger RNA expression and activation of latent TGF-beta. Cell Regul (1991) 1.27
IL-6 induces hepatic inflammation and collagen synthesis in vivo. Clin Exp Immunol (1994) 1.24
The hepatitis B virus encoded oncoprotein pX amplifies TGF-beta family signaling through direct interaction with Smad4: potential mechanism of hepatitis B virus-induced liver fibrosis. Genes Dev (2001) 1.17
Transforming growth factor-beta1 triggers hepatocellular carcinoma invasiveness via alpha3beta1 integrin. Am J Pathol (2002) 1.17
Immunohistochemical localization of transforming growth factor-beta 1 in rats with experimental silicosis, alveolar type II hyperplasia, and lung cancer. Am J Pathol (1993) 1.14
Expression of transforming growth factor-beta 1 and its relation to endomysial fibrosis in progressive muscular dystrophy. Am J Pathol (1994) 1.12
TNFalpha is required for cholestasis-induced liver fibrosis in the mouse. Biochem Biophys Res Commun (2008) 1.11
Stem cell factor restores hepatocyte proliferation in IL-6 knockout mice following 70% hepatectomy. J Clin Invest (2003) 1.09
Active transforming growth factor-beta in wound repair: determination using a new assay. Am J Pathol (1999) 1.08
Cells, matrix, growth factors, and the surgeon. The biology of scarless fetal wound repair. Ann Surg (1994) 1.07
Transforming growth factor-beta1 gene polymorphisms are associated with progression of liver fibrosis in Caucasians with chronic hepatitis C infection. World J Gastroenterol (2005) 1.07
Regression of hepatic fibrosis in hepatitis C with long-term interferon treatment. Dig Dis Sci (1998) 1.05
Hepatitis B virus infection and primary hepatocellular carcinoma. Clin Microbiol Rev (1992) 1.04
Assessment of therapeutic benefit of antiviral therapy in chronic hepatitis C: is hepatic venous pressure gradient a better end point? Gut (2002) 1.01
Medical applications of transforming growth factor-beta. Clin Med Res (2003) 0.97
Novel insights into the function and dynamics of extracellular matrix in liver fibrosis. Am J Physiol Gastrointest Liver Physiol (2015) 0.97
Circulating CO3-610, a degradation product of collagen III, closely reflects liver collagen and portal pressure in rats with fibrosis. Fibrogenesis Tissue Repair (2011) 0.94
Transforming growth factor-beta initiates wound repair in rat liver through induction of the EIIIA-fibronectin splice isoform. Am J Pathol (2000) 0.94
Renal extracellular matrix accumulation in acute puromycin aminonucleoside nephrosis in rats. Am J Pathol (1992) 0.93
CD38-mediated Ca2+ signaling contributes to angiotensin II-induced activation of hepatic stellate cells: attenuation of hepatic fibrosis by CD38 ablation. J Biol Chem (2009) 0.93
Different effects of rat interferon alpha, beta and gamma on rat hepatic stellate cell proliferation and activation. BMC Cell Biol (2002) 0.92
Computational selection and prioritization of candidate genes for fetal alcohol syndrome. BMC Genomics (2007) 0.92
Role of transforming growth factor beta 1 on hepatic regeneration and apoptosis in liver diseases. J Clin Pathol (1995) 0.91
Tumor necrosis factor-alpha inhibits collagen alpha1(I) gene expression and wound healing in a murine model of cachexia. Am J Pathol (1996) 0.91
Serum collagen type VI and XIV and hyaluronic acid as early indicators for altered connective tissue turnover in alcoholic liver disease. Dig Dis Sci (2001) 0.91
Healing of burn wounds in transgenic mice overexpressing transforming growth factor-beta 1 in the epidermis. Am J Pathol (2001) 0.91
Two different cis-acting regulatory regions direct cell-specific transcription of the collagen alpha 1(I) gene in hepatic stellate cells and in skin and tendon fibroblasts. J Clin Invest (1995) 0.90
Hepatoprotection with a chloroform extract of Launaea procumbens against CCl4-induced injuries in rats. BMC Complement Altern Med (2012) 0.90
Plasma TGF beta in systemic sclerosis: a cross-sectional study. Ann Rheum Dis (1994) 0.88
Localisation and semiquantitative assessment of hepatic procollagen mRNA in primary biliary cirrhosis. Gut (1998) 0.87
Putative roles of hepatitis B x antigen in the pathogenesis of chronic liver disease. Cancer Lett (2009) 0.86
Interferon lowers tumor recurrence rate after surgical resection or ablation of hepatocellular carcinoma: a pilot study of patients with hepatitis B virus-related cirrhosis. J Gastroenterol (2007) 0.86
Transforming growth factor (TGF)-beta stimulates hepatic jun-B and fos-B proto-oncogenes and decreases albumin mRNA. Ann Surg (1992) 0.85
Changes in serum cytokine concentration: a morphological study of liver cirrhosis induced by common bile duct ligation in rats. Korean J Intern Med (2003) 0.85
Choline's role in maintaining liver function: new evidence for epigenetic mechanisms. Curr Opin Clin Nutr Metab Care (2013) 0.85
Expression of transforming growth factor-alpha and -beta in hepatic lobes after hemihepatic portal vein embolization. Dig Dis Sci (2006) 0.83
Effects of 18α-glycyrrhizin on TGF-β1/Smad signaling pathway in rats with carbon tetrachloride-induced liver fibrosis. Int J Clin Exp Pathol (2015) 0.83
Effect of pegylated interferon alpha 2b plus ribavirin treatment on plasma transforming growth factor-beta1, metalloproteinase-1, and tissue metalloproteinase inhibitor-1 in patients with chronic hepatitis C. World J Gastroenterol (2005) 0.82
Low-dose intermittent interferon-alpha therapy for HCV-related liver cirrhosis after curative treatment of hepatocellular carcinoma. World J Gastroenterol (2007) 0.82
Alpha-interferon improves liver fibrosis in chronic hepatitis C: clinical significance of the serum N-terminal propeptide of procollagen type III. Dig Dis Sci (2001) 0.82
Clinical evaluation of urinary transforming growth factor-beta1 and serum alpha-fetoprotein as tumour markers of hepatocellular carcinoma. Br J Cancer (1997) 0.81
Hepatic deletion of Smad7 in mouse leads to spontaneous liver dysfunction and aggravates alcoholic liver injury. PLoS One (2011) 0.80
The pathophysiology of Peyronie's disease. Arab J Urol (2013) 0.79
Role of transforming growth factor-[beta]1 in inhibiting endothelial cell proliferation in experimental alcoholic liver disease. Am J Pathol (1996) 0.79
Histological features predictive of liver fibrosis in chronic hepatitis C infection. J Clin Pathol (1996) 0.79
Fucoidan from Fucus vesiculosus protects against alcohol-induced liver damage by modulating inflammatory mediators in mice and HepG2 cells. Mar Drugs (2015) 0.78
Induction of apoptosis in a human hepatocellular carcinoma cell line by a neutralizing antibody to transforming growth factor-alpha. Virchows Arch (1997) 0.78
Acute and chronic immune biomarker changes during interferon/ribavirin treatment in HIV/HCV co-infected patients. J Viral Hepat (2014) 0.78
Initial results with recombinant interferon alfa-2b in patients with chronic hepatitis C: the United States experience. Gut (1993) 0.78
Hepatic fibrosis--new therapeutic approaches. N Engl J Med (1991) 0.77
Improvement of molar ratio of branched-chain amino acids to tyrosine (BTR) associated with liver fibrosis in chronic hepatitis C patients treated with interferon-alpha. Dig Dis Sci (1999) 0.77
Hepatitis D virus isolates with low replication and epithelial-mesenchymal transition-inducing activity are associated with disease remission. J Virol (2012) 0.77
Neonatal brain hemorrhage (NBH) of prematurity: translational mechanisms of the vascular-neural network. Curr Med Chem (2015) 0.76
Neutralization of transforming growth factor beta 1 augments hepatitis C virus-specific cytotoxic T lymphocyte induction in vitro. J Clin Immunol (1997) 0.76
HIV-1 gp160 protein-macrophage interactions modulate mesangial cell proliferation and matrix synthesis. Am J Pathol (1995) 0.76
Overexpression of cyclooxygenase-2 and transforming growth factor-beta 1 is an independent predictor of poor virological response to interferon therapy in chronic HCV genotype 4 patients. Saudi J Gastroenterol (2014) 0.76
Proliferation of intrahepatic bile-duct epithelium in biliary atresia : A useful predictor of clinical outcome. Pediatr Surg Int (2013) 0.75
Treatment of chronic hepatitis C in a patient affected by systemic sclerosis. Gastroenterol Res Pract (2009) 0.75
Changes in serum transforming growth factor-β1 levels in chronic hepatitis C patients under antiviral therapy. Ann Gastroenterol (2016) 0.75
Co-administration of cyclosporine an alleviates thioacetamide-induced liver injury. World J Gastroenterol (2005) 0.75
TGF-β1-509C/T polymorphism and the risk of ESCC in a Chinese Han population. Int J Clin Exp Med (2015) 0.75
High fibrosis indices in cerebrospinal fluid of patients with shunt-dependent post-traumatic chronic hydrocephalus. Transl Neurosci (2016) 0.75
The kinetics of mRNA transforming growth factor beta1 expression and its serum concentration in graft-versus-host disease after allogeneic hemopoietic stem cell transplantation for myeloid leukemias. Med Sci Monit (2011) 0.75
Imbalance of pro- and anti-inflammatory cytokines in pulmonary sarcoidosis. Mediators Inflamm (1996) 0.75
Mechanisms of Accelerated Liver Fibrosis Progression during HIV Infection. J Clin Transl Hepatol (2016) 0.75
Managing patients on interferon therapy. Dig Dis Sci (1996) 0.75
Initiation of liver growth by tumor necrosis factor: deficient liver regeneration in mice lacking type I tumor necrosis factor receptor. Proc Natl Acad Sci U S A (1997) 4.33
TGF alpha overexpression in transgenic mice induces liver neoplasia and abnormal development of the mammary gland and pancreas. Cell (1990) 3.86
Transforming growth factor beta mRNA increases during liver regeneration: a possible paracrine mechanism of growth regulation. Proc Natl Acad Sci U S A (1988) 2.62
Cell lineages and oval cell progenitors in rat liver development. Cancer Res (1991) 2.62
Serum ferritin in patients with iron overload and with acute and chronic liver diseases. Gastroenterology (1975) 2.58
NF-kappaB mediates alphavbeta3 integrin-induced endothelial cell survival. J Cell Biol (1998) 2.49
Ornithine decarboxylase activity and the onset of deoxyribonucleic acid synthesis in regenerating liver. Biochem J (1978) 2.35
Transforming growth factor alpha may be a physiological regulator of liver regeneration by means of an autocrine mechanism. Proc Natl Acad Sci U S A (1989) 2.35
Isolation of multipotent progenitor cells from human fetal liver capable of differentiating into liver and mesenchymal lineages. Proc Natl Acad Sci U S A (2006) 2.32
Oval cell proliferation and the origin of small hepatocytes in liver injury induced by D-galactosamine. Am J Pathol (1991) 2.31
Inflammation and liver cancer: new molecular links . Ann N Y Acad Sci (2009) 2.29
Insulin-like growth factor-I reverts testicular atrophy in rats with advanced cirrhosis. Hepatology (2000) 2.24
Reduced mRNA abundance of the main enzymes involved in methionine metabolism in human liver cirrhosis and hepatocellular carcinoma. J Hepatol (2000) 2.22
Establishment and characterization of differentiated, nontransformed hepatocyte cell lines derived from mice transgenic for transforming growth factor alpha. Proc Natl Acad Sci U S A (1994) 2.20
New therapies for hepatocellular carcinoma. Oncogene (2006) 2.05
Regulated transcription of c-Ki-ras and c-myc during compensatory growth of rat liver. Mol Cell Biol (1984) 1.98
Analysis of liver regeneration in mice lacking type 1 or type 2 tumor necrosis factor receptor: requirement for type 1 but not type 2 receptor. Hepatology (1998) 1.96
Partial splenic embolization for the treatment of hypersplenism in cirrhosis. Hepatology (1993) 1.95
Expression of a cellular oncogene during liver regeneration. Science (1983) 1.88
Pathological and virological findings in patients with persistent hypertransaminasaemia of unknown aetiology. Gut (2000) 1.82
Rapid DNA binding by nuclear factor kappa B in hepatocytes at the start of liver regeneration. Cell Growth Differ (1995) 1.75
Transduction of hepatocellular carcinoma (HCC) using recombinant adeno-associated virus (rAAV): in vitro and in vivo effects of genotoxic agents. J Hepatol (2000) 1.73
Expression of suppressors of cytokine signaling during liver regeneration. J Clin Invest (2001) 1.71
Impaired preneoplastic changes and liver tumor formation in tumor necrosis factor receptor type 1 knockout mice. J Exp Med (2000) 1.68
Cellular immunity to hepatitis C virus core protein and the response to interferon in patients with chronic hepatitis C. Hepatology (1998) 1.67
Serum ferritin assay and iron status in chronic renal failure and haemodialysis. Br Med J (1975) 1.61
Tumor necrosis factor primes hepatocytes for DNA replication in the rat. Hepatology (1998) 1.60
The problem of aging human remains and living individuals: a review. Forensic Sci Int (2009) 1.59
Adenovirus-mediated CD40 ligand gene therapy in a rat model of orthotopic hepatocellular carcinoma. Hepatology (2001) 1.56
Tumor necrosis factor alpha gene expression and the response to interferon in chronic hepatitis C. Hepatology (1996) 1.56
Isolation of oval cells by centrifugal elutriation and comparison with other cell types purified from normal and preneoplastic livers. Cancer Res (1984) 1.52
Prevention of hepatic apoptosis and embryonic lethality in RelA/TNFR-1 double knockout mice. Am J Pathol (2000) 1.46
Deficient liver regeneration after carbon tetrachloride injury in mice lacking type 1 but not type 2 tumor necrosis factor receptor. Am J Pathol (1998) 1.45
Liver transplantation in cirrhotic patients with diabetes mellitus: midterm results, survival, and adverse events. Liver Transpl (2001) 1.44
Magnesium binding to the bacterial chemotaxis protein CheY results in large conformational changes involving its functional surface. J Mol Biol (1994) 1.44
Sequential protooncogene expression during rat liver regeneration. Cancer Res (1986) 1.42
Generation of hepatocytes from oval cell precursors in culture. Cancer Res (1998) 1.41
Rituximab in CD20 positive multiple myeloma. Leukemia (2007) 1.40
Liver transplantation in cirrhotic patients over 60 years of age. Rev Esp Enferm Dig (1998) 1.38
In vivo response of hepatocytes to growth factors requires an initial priming stimulus. Hepatology (1994) 1.38
Tumor necrosis factor induces DNA replication in hepatic cells through nuclear factor kappaB activation. Cell Growth Differ (1999) 1.37
Nuclear factor-kappaB/Rel blocks transforming growth factor beta1-induced apoptosis of murine hepatocyte cell lines. Cell Growth Differ (1997) 1.36
Immunohistochemical detection of chloride/bicarbonate anion exchangers in human liver. Hepatology (1994) 1.32
Effects of specific antibodies against Streptococcus pneumoniae on pharmacodynamic parameters of beta-lactams in a mouse sepsis model. Antimicrob Agents Chemother (2002) 1.32
The control of ornithine decarboxylase activity during liver regeneration. Biochim Biophys Acta (1971) 1.32
Isozyme profiles of oval cells, parenchymal cells, and biliary cells isolated by centrifugal elutriation from normal and preneoplastic livers. Cancer Res (1984) 1.32
Transforming growth factor-beta (TGF-beta) isoforms in rat liver regeneration: messenger RNA expression and activation of latent TGF-beta. Cell Regul (1991) 1.27
c-myc, c-fos, and c-jun regulation in the regenerating livers of normal and H-2K/c-myc transgenic mice. Mol Cell Biol (1990) 1.27
Cell lineages in liver carcinogenesis: possible clues from studies of the distribution of alpha-fetoprotein RNA sequences in cell populations isolated from normal, regenerating, and preneoplastic rat livers. Cancer Res (1985) 1.25
Hepatoprotective effects of insulin-like growth factor I in rats with carbon tetrachloride-induced cirrhosis. Gastroenterology (1997) 1.25
Influence of tumor characteristics on the outcome of liver transplantation among patients with liver cirrhosis and hepatocellular carcinoma. Liver Transpl (2001) 1.25
Prediction of sustained remission of chronic hepatitis C after a 12-month course of alfa interferon. J Hepatol (1994) 1.25
Expression of c-Ki-ras, c-Ha-ras, and c-myc in specific cell types during hepatocarcinogenesis. Mol Cell Biol (1985) 1.22
Systemic and regional hemodynamics in patients with liver cirrhosis and ascites with and without functional renal failure. Gastroenterology (1989) 1.20
Leukocyte-cell adhesion: a molecular process fundamental in leukocyte physiology. Immunol Rev (1990) 1.18
Inhibition of NF-kappa B activity induces apoptosis in murine hepatocytes. Am J Pathol (1997) 1.18
Streptococcus pneumoniae isolates with reduced susceptibility to ciprofloxacin in Spain: clonal diversity and appearance of ciprofloxacin-resistant epidemic clones. Antimicrob Agents Chemother (2001) 1.18
Adenovirus-mediated urokinase gene transfer induces liver regeneration and allows for efficient retrovirus transduction of hepatocytes in vivo. Proc Natl Acad Sci U S A (1995) 1.18
Intratumoral coinjection of two adenoviruses, one encoding the chemokine IFN-gamma-inducible protein-10 and another encoding IL-12, results in marked antitumoral synergy. J Immunol (2000) 1.17
Effect of killer immunoglobulin-like receptors in the response to combined treatment in patients with chronic hepatitis C virus infection. J Virol (2010) 1.15
What's in a Name? The American Society for Investigative Pathology. Am J Pathol (1993) 1.15
Implication of human N-alpha-acetyltransferase 5 in cellular proliferation and carcinogenesis. Oncogene (2008) 1.15
Bcl-2 delays and alters hepatic carcinogenesis induced by transforming growth factor alpha. Cancer Res (2001) 1.14
Transmission of hepatitis C virus infection to tree shrews. Virology (1998) 1.14
Growth in culture and tumorigenicity after transfection with the ras oncogene of liver epithelial cells from carcinogen-treated rats. Cancer Res (1987) 1.13
Overexpression of transforming growth factor-alpha causes liver enlargement and increased hepatocyte proliferation in transgenic mice. Am J Pathol (1994) 1.13
Production of hepatocellular carcinoma by oval cells: cell cycle expression of c-myc and p53 at different stages of oval cell transformation. Cancer Res (1989) 1.13
Studies on ornithine decarboxylase activity in normal and regenerating livers. Biochim Biophys Acta (1969) 1.12
Induction of cytotoxic T lymphocytes in mice against the principal neutralizing domain of HIV-1 by immunization with an engineered T-cytotoxic-T-helper synthetic peptide construct. Cell Immunol (1992) 1.12
Autonomous growth in serum-free medium and production of hepatocellular carcinomas by differentiated hepatocyte lines that overexpress transforming growth factor alpha 1. Cancer Res (1994) 1.11
Hepatitis B and C viral infections in patients with hepatocellular carcinoma. Hepatology (1992) 1.10
Development of liver tumors in transforming growth factor alpha transgenic mice. Cancer Res (1992) 1.10
Disruption of redox homeostasis in tumor necrosis factor-induced apoptosis in a murine hepatocyte cell line. Am J Pathol (2000) 1.09
Amphiregulin: a new growth factor in hepatocarcinogenesis. Cancer Lett (2007) 1.08
Osteopenia in rats with liver cirrhosis: beneficial effects of IGF-I treatment. J Hepatol (1998) 1.07
Identification of a novel adhesion molecule in human leukocytes by monoclonal antibody LB-2. FEBS Lett (1987) 1.05
Molecular and genetic analysis of liver oncogenesis in transforming growth factor alpha transgenic mice. Cancer Res (1992) 1.05
Enhanced acetaminophen hepatotoxicity in transgenic mice overexpressing BCL-2. Mol Pharmacol (2001) 1.05
Hepatic and extrahepatic HCV RNA strands in chronic hepatitis C: different patterns of response to interferon treatment. Hepatology (1993) 1.05
Liver cytoprotection by prostaglandins. Pharmacol Ther (1993) 1.05
Gene therapy of orthotopic hepatocellular carcinoma in rats using adenovirus coding for interleukin 12. Hepatology (2001) 1.04
Expression of Bcl-2 family during liver regeneration and identification of Bcl-x as a delayed early response gene. Am J Pathol (1997) 1.03
Transjugular intrahepatic portal-systemic shunt in the treatment of refractory ascites: effect on clinical, renal, humoral, and hemodynamic parameters. Hepatology (1995) 1.03
Induction of replicative competence ("priming") in normal liver. Cancer Res (1990) 1.03
The expression of human intercellular adhesion molecule-2 is refractory to inflammatory cytokines. Eur J Immunol (1991) 1.02
alpha-Fetoprotein and albumin mRNA levels in liver regeneration and carcinogenesis. J Biol Chem (1983) 1.02
A phase I clinical trial of thymidine kinase-based gene therapy in advanced hepatocellular carcinoma. Cancer Gene Ther (2010) 1.02
Thermodynamic analysis of the chemotactic protein from Escherichia coli, CheY. Biochemistry (1993) 1.02
Insulin-like growth factor I improves intestinal barrier function in cirrhotic rats. Gut (2006) 1.02
Oncogene expression in liver regeneration and hepatocarcinogenesis. Hepatology (1983) 1.02
The response of the hepatocyte to ischemia. Liver Int (2007) 1.01
Activity of fluconazole: postantifungal effect, effects of low concentrations and of pretreatment on the susceptibility of Candida albicans to leucocytes. J Antimicrob Chemother (1994) 1.01
Immunization with a tumor-associated CTL epitope plus a tumor-related or unrelated Th1 helper peptide elicits protective CTL immunity. Eur J Immunol (2001) 1.01
Polarity of immunogens: implications for vaccine design. Eur J Immunol (1990) 1.00
Treatment of colorectal and hepatocellular carcinomas by adenoviral mediated gene transfer of endostatin and angiostatin-like molecule in mice. Gut (2004) 1.00
Viremia after one month of interferon therapy predicts treatment outcome in patients with chronic hepatitis C. Gastroenterology (1997) 1.00
In vitro effect of the presence of human albumin or human serum on the bactericidal activity of daptomycin against strains with the main resistance phenotypes in Gram-positives. J Antimicrob Chemother (2007) 1.00